Myelin oligodendrocyte glycoprotein antibody-associated disease (mogad)
Clinical trials for Myelin oligodendrocyte glycoprotein antibody-associated disease (mogad) explained in plain language.
Never miss a new study
Get alerted when new Myelin oligodendrocyte glycoprotein antibody-associated disease (mogad) trials appear
Sign up with your email to follow new studies for Myelin oligodendrocyte glycoprotein antibody-associated disease (mogad), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug aims to stop relapses in rare brain disease
Disease control OngoingThis phase 3 trial tests whether satralizumab can prevent relapses in people with MOGAD, a rare disease where the immune system attacks the brain and spinal cord. About 152 participants aged 12 and older will receive either the drug or a placebo. The main goal is to see if satral…
Matched conditions: MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Promising drug aims to stop Flare-Ups in rare brain disease
Disease control OngoingThis study tests an investigational drug called rozanolixizumab in adults with MOG antibody-associated disease (MOGAD), a rare condition where the immune system attacks the brain and spinal cord. The main goal is to see if the drug can prevent or delay relapses (flare-ups) compar…
Matched conditions: MYELIN OLIGODENDROCYTE GLYCOPROTEIN ANTIBODY-ASSOCIATED DISEASE (MOGAD)
Phase 3 • Sponsor: UCB Biopharma SRL • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC